Protalix BioTherapeutics, Inc.
PLX
$1.93
$0.021.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.23% | 35.42% | 62.79% | 0.18% | -18.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.23% | 35.42% | 62.79% | 0.18% | -18.47% |
| Cost of Revenue | 25.02% | -15.27% | -8.15% | 8.92% | -6.61% |
| Gross Profit | -58.91% | 37,317.74% | 671.40% | -16.09% | -36.25% |
| SG&A Expenses | -4.19% | -16.36% | -24.92% | -21.91% | -18.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.71% | 1.65% | 1.67% | 6.87% | -10.09% |
| Operating Income | -240.41% | 171.48% | 155.64% | -42.60% | -62.55% |
| Income Before Tax | -235.00% | 167.63% | 153.39% | -23.84% | -51.51% |
| Income Tax Expenses | -18.49% | 5,955.56% | 497.59% | 1,678.48% | 381.10% |
| Earnings from Continuing Operations | -325.24% | 156.15% | 142.70% | -42.93% | -64.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -325.24% | 156.15% | 142.70% | -42.93% | -64.73% |
| EBIT | -240.41% | 171.48% | 155.64% | -42.60% | -62.55% |
| EBITDA | -177.28% | 202.03% | 170.94% | -35.93% | -55.19% |
| EPS Basic | -294.48% | 158.32% | 145.29% | -49.10% | -65.12% |
| Normalized Basic EPS | -218.47% | 169.94% | 155.88% | -33.43% | -53.04% |
| EPS Diluted | -14,216.67% | 132.90% | 122.06% | -21.26% | -97.94% |
| Normalized Diluted EPS | -437.04% | 141.82% | 137.58% | -39.49% | -71.64% |
| Average Basic Shares Outstanding | 8.26% | 4.19% | 2.68% | 3.02% | 7.63% |
| Average Diluted Shares Outstanding | -4.12% | 14.27% | 13.44% | 7.30% | 11.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |